Are you a man or a transgender person who has sex with men?
We want to talk to you!
Globally HIV transmission is still a serious health issue that needs a lot of attention from governments, health care providers, and our communities. There are general services, educational campaigns and programmes for all members of society. However, men and transgender people who have sex with men are particularly at risk of HIV infection. This is a real problem because, as you know, you are often the people with the least access to prevention, care and treatment services because of stigma, discrimination and other social issues. Clearly, special measures needed to be put in place to offer you protection and one of these is more effective HIV pre-exposure prophylaxis options.
Currently, in South Africa, PrEP comes as a tablet that you take every day. This tablet contains anti-HIV drugs and is effective if no doses are missed. It can lower your risk of getting HIV infection by more than 90%. But are there potentially more convenient PrEP options?
Study Context
PURPOSE 2 is a large scale clinical trial to evaluate one such option with a new investigational PrEP drug. This study examines whether a long-acting form of the anti-HIV drug injected once every six months under the skin, can safely protect people from getting HIV infection.
The study is taking place at several sites in many countries around the world including the United States, Brazil, Peru, and South Africa. In South Africa, one of the trial sites is the Desmond Tutu Health Foundation Groote Schuur Clinical Trials Unit in Observatory, Cape Town.
Taking Part
Are you 18 or older and a man or transgender woman or man who has receptive anal sex with men?
Would you be interested in taking part in our study?
Then please go to the PURPOSE 2 website at https://www.purposestudies.com/purpose2/ to get more info and see if this trial is good for you. If you think it is, please call or email us.
Cell: Amelia @ 060 821 8757
Email: [email protected]
